Sector Expert: Joseph Patti
Dr. Joseph M. Patti is president and CEO of Biota Pharmaceuticals Inc. Prior to joining the company, Dr. Patti cofounded Inhibitex, Inc. in 1998 and served as its chief scientific officer and senior vice president of research and development from 2007 until it was acquired by Bristol Myers Squibb in February 2012. Before co-founding Inhibitex, Dr. Patti was an assistant professor at Texas A&M's Institute of Biosciences and Technology and also served on the faculty at the University of Texas Health Science Center Graduate School of Biomedical Sciences. Dr. Patti is currently a director of SciStem Therapeutics, Inc., a privately-held company focused on developing cellular therapies for bone healing and musculoskeletal indications in both human and animal health. He received a B.S. in Microbiology from the University of Pittsburgh, an M.S.P.H. from the University of Miami, School of Medicine and a Ph.D. in Biochemistry from the University of Alabama at Birmingham.
Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. Dr. Joseph M. Patti, CEO of Biota Pharmaceuticals Inc., tells The Life Sciences Report about the novel antiviral therapies in his company's pipeline that address the cause of viral conditions, rather than merely the symptoms.